Moleculin Announces Intent to Expand Annamycin Planned Clinical Trial to Include Sites in Poland Jun 15, 2017
Moleculin Announces Preparation to File an IND with the FDA for WP1220 for Treatment of Cutaneous T-Cell Lymphoma Jun 13, 2017
Moleculin Biotech Issues Shareholder Update on FDA Designation of Orphan Drug and IND Status for Annamycin May 23, 2017
Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2017 May 15, 2017
Moleculin Biotech, Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 Apr 3, 2017
